STOCKHOLM, 5 May, 2020 – The 2019 Annual report of Promore Pharma AB (publ) is now available on the company website.
The annual report is available in PDF format on the company website at: https://www.promorepharma.com/en/section/investors/financial-reports/
Printed copies can be ordered from Promore Pharma AB, Fogdevreten 2, SE-171 65 Solna, or by e-mail: info@promorepharma.com
For additional information, please contact
Jonas Ekblom, VD
Tel: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Jenni Björnulfson, CFO
Tel: [+46] 708 55 38 05
E-mail: jenni.bjornulfson@promorepharma.com
The information was submitted for publication, through the agency of the contact persons set out above, on 5 May 2020 at 16.00 CET.
Promore Pharma’s Certified Adviser is Redeye.
Tel: [+46] 8 121 576 90
E-mail: certifiedadviser@redeye.se
Promore Pharma in brief:
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 is being evaluated in a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.